36. What is this passage mainly about? (A) To argue that oral GLP-1 medications are clinically superior to injectable formulations (B) To discuss the production of the first FDA-approved oral obesity drug (C) To critique the pharmaceutical industry’s commodification of obesity (D) To compare efficiencies between fungal fermentation and synthetic drug production